Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005059 · ClinicalTrials.gov registry record · Phase 2

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
51
Enrollment target
18
Study locations

NCT00005059: Completed Phase 2 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.

NCT00005059 is a Phase 2 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 51 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005059, a Phase 2 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
51 participants
Enrollment target
18
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients who have metastatic or recurrent unresectable non-small cell lung cancer.

Conditions Studied

Interventions

  • DRUG carboplatin
  • DRUG paclitaxel

Study Locations (18)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Clinic - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

North Dakota

  • Quain & Ramstad Clinic, P.C. - Bismarck
  • CCOP - Merit Care Hospital - Fargo

South Dakota

  • Rapid City Regional Hospital - Rapid City
  • CCOP - Sioux Community Cancer Consortium - Sioux Falls

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Kansas

  • CCOP - Wichita - Wichita

Michigan

  • Ann Arbor Hematology Oncology - Ypsilanti

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2000-01
Est. Completion 2006-04
Phase Phase 2

What the finished NCT00005059 record still lists

NCT00005059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.

NCT00005059 lists 18 locations in 10 states (Minnesota, Iowa, Illinois).

Frequently Asked Questions

What is clinical trial NCT00005059 about?

NCT00005059 is a clinical study titled "Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients who have metastatic o...

What is the current status of trial NCT00005059?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2000-01. Estimated completion is 2006-04.

What conditions does trial NCT00005059 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00005059?

The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG).

Who is sponsoring clinical trial NCT00005059?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005059 being conducted?

This trial has 18 study locations across Arizona, Illinois, Iowa, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00005059's enrollment target sits among peer trials

51 262nd of 409 higher than 147 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00005059, the US trial registry maintained by the National Library of Medicine. NCT00005059 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.